Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation.

@article{Ma2004ReductionOR,
  title={Reduction of rat prostate weight by combined quercetin-finasteride treatment is associated with cell cycle deregulation.},
  author={Zengshuan Ma and Thanh Hung Nguyen and Thanh Hoa Huynh and Phuc Tien Do and H. Huynh},
  journal={The Journal of endocrinology},
  year={2004},
  volume={181 3},
  pages={
          493-507
        }
}
  • Zengshuan Ma, Thanh Hung Nguyen, +2 authors H. Huynh
  • Published 2004
  • Biology, Medicine
  • The Journal of endocrinology
  • Benign prostate hyperplasia and prostate cancer are major public health problems. We report herein that daily treatment of male rats with 50, 100 or 150 mg quercetin per kg body weight resulted in serum concentrations of quercetin equivalent to 25.3 microM, 43.3 microM and 54.3 microM respectively. Concomitantly, serum testosterone levels were increased by 1.79-, 1.83- and 3.48-fold, while serum dihydrotestosterone (DHT) levels were 125%, 92% and 73% of the control. A slight increase in… CONTINUE READING
    35 Citations
    Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth and inducing apoptosis in human prostate cancer cells.
    • 26
    • PDF
    Does Tadalafil Increase The Uptake of Finasteride into Prostate Tissue? A Biochemical and Histological Evaluation in Rats.
    Immunomodulatory Effect of Red Onion (Allium cepa Linn) Scale Extract on Experimentally Induced Atypical Prostatic Hyperplasia in Wistar Rats
    • 16
    • PDF

    References

    SHOWING 1-10 OF 67 REFERENCES
    Quercetin regulates growth of Ishikawa cells through the suppression of EGF and cyclin D1.
    • 44
    Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis.
    • 165
    • PDF
    Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin.
    • 311
    • Highly Influential
    Plasma metabolites of quercetin and their antioxidant properties.
    • 294
    • PDF
    Pathologic changes associated with androgen deprivation therapy for prostate cancer
    • 151